A Prospective, Randomised, Multi-centre Phase II Study Evaluating the Adjuvant, Neoadjuvant or Palliative Treatmant With Tamoxifen +/- GnRH Analogue Versus Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Exemestane (Primary) ; Goserelin; Leuprorelin; Tamoxifen
- Indications Male breast cancer
- Focus Therapeutic Use
- Acronyms MALE
- 25 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 09 Feb 2016 Planned End Date changed from 1 Mar 2015 to 1 Mar 2018 as reported by ClinicalTrials.gov.